DOVITINIB LACTATE
Total Payments
$107,741
Transactions
18
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $11,252 | 4 | 4 |
| 2019 | $27,080 | 4 | 0 |
| 2018 | $4,140 | 2 | 0 |
| 2017 | $65,269 | 8 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $107,741 | 18 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE II STUDY OF TKI258 DOVITINIB IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA WHO HAVE PROGRESSED ON ANTI ANGIOGENIC THERAPY INCLUDING ANTI VEGF THERAPY | Novartis Pharmaceuticals Corporation | $30,122 | 0 |
| A PHASE I AND OR II STUDY OF DOVITINIB TKI258 COMBINED WITH ABIRATERONE ACETATE IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER EVALUATING MARKERS OF FGF AND AR SIGNALING IN BONE MARROW AND PLASMA | Novartis Pharmaceuticals Corporation | $15,623 | 0 |
| A PHASE II STUDY OF TKI258 DOVITINIB LACTATE AS SALVAGE THERAPY IN PATIENTS WITH STAGE IV HER2 NEGATIVE IBC WITH LOCAL OR DISTANT RELAPSE | Novartis Pharmaceuticals Corporation | $13,015 | 0 |
| A PHASE I AND OR II TRIAL OF TKI258 DOVITINIB IN COMBINATION WITH AN AROMATASE INHIBITOR IN PATIENTS WITH METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $12,650 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $11,252 | 4 |
| AN OPEN LABEL MULTI CENTER EXTENSION STUDY TO EVALUATE LONG TERM SAFETY AND TOLERABILITY OF DOVITINIB IN PATIENTS WITH SOLID TUMORS WHO CONTINUE TO RECEIVE TREATMENT WITH DOVITINIB TKI258 IN NOVARTIS SPONSORED SINGLE AGENT DOVITINIB STUDIES WHICH HAVE FULFILLED THE REQUIREMENTS FOR THE PRIMARY OBJECTIVE AND ARE BENEFITTING FROM CONTINUEDDOVITINIB TREATMENT AS ASSESSED BY THE INVESTIGATOR | Novartis Pharmaceuticals Corporation | $7,047 | 0 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF TKI258 COMBINED WITH FULVESTRANT IN POSTMENOPAUSAL PATIENTS WITH HER2 AND HR PLUS BREAST CANCER THAT HAVE EVIDENCE OF DISEASE PROGRESSION ON OR AFTER PRIOR ENDOCRINE THERAPY | Novartis Pharmaceuticals Corporation | $6,726 | 0 |
| A PHASE II MULTI CENTER NON RANDOMIZED OPEN LABEL STUDY OF TKI258 IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO ARE WITH OR WITHOUT T4 14 TRANSLOCATION | Novartis Pharmaceuticals Corporation | $5,732 | 0 |
| A PHASE II OPEN LABEL SINGLE ARM NON RANDOMIZED MULTICENTER STUDY TO EVALUATE THE EFFICACY OF ORAL TKI258 AS SECOND LINE THERAPY IN PATIENTS WITH EITHER FGFR2 MUTATED OR WILD TYPE ADVANCED AND OR METASTATIC ENDOMETRIAL CANCER | Novartis Pharmaceuticals Corporation | $4,445 | 0 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF TKI258 COMBINED WITH FULVESTRANT IN POSTMENOPAUSAL PATIENTS WITH HER2 AND HR PLUS BREAST CANCER THAT HAVE EVIDENCE OF DISEASE PROGRESSION ON OR A | Novartis Pharmaceuticals Corporation | $1,129 | 0 |
Top Doctors Receiving Payments for DOVITINIB LACTATE
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $107,741
Product Information
- Type Drug
- Total Payments $107,741
- Total Doctors 4
- Transactions 18
About DOVITINIB LACTATE
DOVITINIB LACTATE is a drug associated with $107,741 in payments to 4 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $11,252 was paid across 4 transactions to 4 doctors.
The most common payment nature for DOVITINIB LACTATE is "Unspecified" ($107,741, 100.0% of total).
DOVITINIB LACTATE is associated with 10 research studies, including "PHASE II STUDY OF TKI258 DOVITINIB IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA WHO HAVE PROGRESSED ON ANTI ANGIOGENIC THERAPY INCLUDING ANTI VEGF THERAPY" ($30,122).